A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
Open accessThe DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
An HIV antibody achieves potency and breadth by binding simultaneously to two conserved glycans on the viral envelope protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by speci fi c antibodies, such as that seen on the surface of the HIV virion (507 -509, 594).”
From Biological roles of glycans (2017) · cites this paper as [508]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
EMAN2: An extensible image processing suite for electron microscopy
Tang, G., Peng, L., Baldwin, P. R., Mann, D. S., Jiang, W., Rees, I., & Ludtke, S. J. (2007) · Journal of Structural Biology · doi:10.1016/j.jsb.2006.05.009 · Cited by 2,994
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31405 · Cited by 2,964
EMAN: Semiautomated Software for High-Resolution Single-Particle Reconstructions
Ludtke, S. J., Baldwin, P. R., & Chiu, W. (1999) · Journal of Structural Biology · doi:10.1006/jsbi.1999.4174 · Cited by 2,391
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Self-citationBroad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L. M., Phogat, S. K., Chan-Hui, P.-Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,723
Self-citation
Cited by
Items 101–200 of 709
Kong, R., Louder, M. K., Wagh, K., Bailer, R. T., deCamp, A. C., Greene, K., Gao, H., Taft, J. D., Gazumyan, A., Liu, C., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03136-14 · Cited by 140
Antibody B cell responses in HIV-1 infection
Mouquet, H. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.08.007 · Cited by 145
Ping, L., Joseph, S., Anderson, J. A., Abrahams, M.-R., Salazar-Gonzalez, J. F., Kincer, L. P., Treurnicht, F. K., Arney, L., Ojeda, S., Zhang, M., et al. (2013) · Journal of Virology · doi:10.1128/jvi.03577-12 · Cited by 154
“There are several examples where inclusion of part of the carbohydrate structure into the epitope has resulted in an antibody that has broad neutralizing capacity, such as the monoclonal antibody 2G12 (98, 99), the monoclonal antibody PGT 128, which shows a specificity for the presence of a glycan at position 332 (100…”
BackgroundPritchard, L. K., Spencer, D. I. R., Royle, L., Bonomelli, C., Seabright, G. E., Behrens, A.-J., Kulp, D. W., Menis, S., Krumm, S. A., Dunlop, D. C., et al. (2015) · Nature Communications · doi:10.1038/ncomms8479 · Cited by 125
“A number of the best characterized glycan-binding bnAbs to date have been found to specifically target the N332 glycan 9,17,19-21 , although it is now believed that the area of vulnerability extends across Env 11,12,16,24,25,43 .”
InfluentialSelf-citationPolyreactive antibodies in adaptive immune responses to viruses
Mouquet, H., & Nussenzweig, M. C. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0872-6 · Cited by 138
Saunders, K. O., Wang, L., Joyce, M. G., Yang, Z.-Y., Balazs, A. B., Cheng, C., Ko, S.-Y., Kong, W.-P., Rudicell, R. S., Georgiev, I. S., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00908-15 · Cited by 122
Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen
Struwe, W. B., Chertova, E., Allen, J. D., Seabright, G. E., Watanabe, Y., Harvey, D. J., Medina-Ramirez, M., Roser, J. D., Smith, R., Westcott, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.080 · Cited by 125
“The N332-glycan is a ‘‘supersite of vulnerability’’ in that it is a key component of multiple bnAb epitopes (Kong et al., 2013; Pejchal et al., 2011).”
BackgroundSelf-citationEffect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein
Chen, J., Kovacs, J. M., Peng, H., Rits-Volloch, S., Lu, J., Park, D., Zablowsky, E., Seaman, M. S., & Chen, B. (2015) · Science · doi:10.1126/science.aaa9804 · Cited by 125
Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies
McGuire, A. T., Dreyer, A. M., Carbonetti, S., Lippy, A., Glenn, J., Scheid, J. F., Mouquet, H., & Stamatatos, L. (2014) · Science · doi:10.1126/science.1259206 · Cited by 123
Modular synthesis of N-glycans and arrays for the hetero-ligand binding analysis of HIV antibodies
Shivatare, S. S., Chang, S., Tsai, T.-I., Tseng, S. Y., Shivatare, V. S., Lin, Y., Cheng, Y., Ren, C., Lee, C.-C. D., Pawar, S., et al. (2016) · Nature Chemistry · doi:10.1038/nchem.2463 · Cited by 127
Self-citationInsights into the trimeric HIV-1 envelope glycoprotein structure
Ward, A. B., & Wilson, I. A. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.12.006 · Cited by 130
“Multiple bnAbs that recognize this site bind to the same glycan (N332), but use different angles of approach and different combinations of the surrounding glycans for interaction (9, 19, 25, 36, 41, 46) [Fig 3A].”
BackgroundSelf-citationCD4-Induced Activation in a Soluble HIV-1 Env Trimer
Guttman, M., Garcia, N. K., Cupo, A., Matsui, T., Julien, J., Sanders, R. W., Wilson, I. A., Moore, J. P., & Lee, K. K. (2014) · Structure · doi:10.1016/j.str.2014.05.001 · Cited by 123
“Collectively, these observations may be relevant to immunogen design as several of these glycans are involved in bNAb epitopes (Jardine et al., 2013; Pancera et al., 2013; Pejchal et al., 2011; Walker et al., 2011).”
BackgroundSelf-citationBroadly neutralizing antibodies against HIV-1: Templates for a vaccine
van Gils, M. J., & Sanders, R. W. (2012) · Virology · doi:10.1016/j.virol.2012.10.004 · Cited by 125
Self-citationStrategies to guide the antibody affinity maturation process
Doria‐Rose, N. A., & Joyce, M. G. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.04.002 · Cited by 136
“Current Opinion in Virology 2015, 11:137–147 molecule [11,25,26 ,27].”
Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1
Yu, L., & Guan, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00250 · Cited by 123
Wang, W., Nie, J., Prochnow, C., Truong, C., Jia, Z., Wang, S., Chen, X. S., & Wang, Y. (2013) · Retrovirology · doi:10.1186/1742-4690-10-14 · Cited by 114
“PGT128 recognizes two conserved glycans at N301/N332 as well as a short β-strand segment of the gp120 V3 loop [55].”
Self-citationPotential neutralizing antibodies discovered for novel corona virus using machine learning
Magar, R., Yadav, P., & Barati Farimani, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-84637-4 · Cited by 114
Barnes, C. O., Gristick, H. B., Freund, N. T., Escolano, A., Lyubimov, A. Y., Hartweger, H., West, A. P., Cohen, A. E., Nussenzweig, M. C., & Björkman, P. J. (2018) · Nature Communications · doi:10.1038/s41467-018-03632-y · Cited by 117
“Engagement of the carboxylate group of D325gp120 is achieved by residues in CDRL2 (BG18) or serine residues in CDRs L1 and L3 (10-1074).”
BackgroundStructural analysis of glycoproteins: building N-linked glycans with Coot
Emsley, P., & Crispin, M. (2018) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798318005119 · Cited by 116
“This trend includes a growing number of examples of glycans that are braced against protein surfaces, including by antibody binding (Pejchal et al., 2011), and by the advent of methods to manufacture chemically homogenous glycoforms for structural analysis (Chang et al., 2007).”
MethodSelf-citationProtein and Glycan Mimicry in HIV Vaccine Design
Seabright, G. E., Doores, K. J., Burton, D. R., & Crispin, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.016 · Cited by 115
Self-citationSynthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies
Amin, M. N., McLellan, J. S., Huang, W., Orwenyo, J., Burton, D. R., Koff, W. C., Kwong, P. D., & Wang, L. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1288 · Cited by 115
“X-ray X-ray structural studies on antibodies PGT127 and PGT128 Fabs and their complexes with a recombinant gp120 outer domain also show a similar antigen recognition mode, with two glycans and a peptide motif in the V3 domain as the essential components of the epitopes of PGT127/128 14 .”
Self-citationRecapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth
Roark, R. S., Li, H. J., Williams, W. B., Chug, H., Mason, R. D., Gorman, J., Wang, S., Lee, F.-H., Rando, J. M., Bonsignori, M., et al. (2020) · Science · doi:10.1126/science.abd2638 · Cited by 114
“CH848-infected RMs 6167 and 6163 targeted canonical N332 and (324)GDIR(327)motifs, similar to humanV3 glycan bNAbs (78, 79).”
BackgroundSelf-citationRecent strategies targeting HIV glycans in vaccine design
Horiya, S., MacPherson, I. S., & Krauss, I. J. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1685 · Cited by 108
VanBlargan, L. A., Goo, L., & Pierson, T. C. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00024-15 · Cited by 118
Landais, E., Murrell, B., Briney, B. S., Murrell, S., Rantalainen, K. I., Berndsen, Z. T., Ramos, A. G., Wickramasinghe, L., Smith, M. L., Eren, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.002 · Cited by 107
“Although most V2-apex bnAbs appear to share important structural features (Andrabi et al., 2015; Doria-Rose et al., 2014; Gorman et al., 2016; Pejchal et al., 2011; Sok et al., 2014), it is not clear whether commonalities also arise in their development.”
BackgroundSelf-citationRademeyer, C., Korber, B., Seaman, M. S., Giorgi, E. E., Thebus, R., Robles, A., Sheward, D. J., Wagh, K., Jetta, G., Carey, B. R., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005742 · Cited by 112
“Modelling the contribution of N332 and infection stage on neutralization sensitivity of viruses.”
BackgroundInfluentialStructural principles controlling HIV envelope glycosylation
Behrens, A., & Crispin, M. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2017.03.008 · Cited by 111
“reaching in between glycans and incorporating them into their epitopes [8,53] (Figure 4B).”
Self-citationPeptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Advances in antiviral vaccine development
Graham, B. S. (2013) · Immunological Reviews · doi:10.1111/imr.12098 · Cited by 101
“Human monoclonal antibodies have now been obtained for the four known antigenic sites on HIV gp160 associated with broad neutralization (41, 55–57), and the structures of the antibody interacting with the antigenic sites have been solved (26, 55, 57, 58).”
BackgroundAdvances in structure-based vaccine design
Kulp, D. W., & Schief, W. R. (2013) · Current Opinion in Virology · doi:10.1016/j.coviro.2013.05.010 · Cited by 112
Self-citationVirological features associated with the development of broadly neutralizing antibodies to HIV-1
Moore, P. L., Williamson, C. E., & Morris, L. (2015) · Trends in Microbiology · doi:10.1016/j.tim.2014.12.007 · Cited by 113
Emerging roles of protein mannosylation in inflammation and infection
Loke, I., Kolarich, D., Packer, N. H., & Thaysen‐Andersen, M. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.04.004 · Cited by 109
Fuchs, S. P., Martinez-Navio, J. M., Piatak, M., Lifson, J. D., Gao, G., & Desrosiers, R. C. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005090 · Cited by 99
“More than a dozen potent broadly neutralizing anti-HIV-1 monoclonal antibodies have already been characterized; they are human-derived, they can effectively neutralize more than 90% of circulating HIV-1 strains, and they represent a range of different specificities [14–21].”
BackgroundHIV-1 envelope glycoprotein structure
Merk, A., & Subramaniam, S. (2013) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2013.03.007 · Cited by 89
“The 3TYG structure was excluded because it does not contain the inner domain of gp120, although the rest of the polypeptide assumes the same conformation as the structures shown here [22].”
BackgroundStructural insights into key sites of vulnerability on HIV‐1 Env and influenza HA
Julien, J., Lee, P. S., & Wilson, I. A. (2012) · Immunological Reviews · doi:10.1111/imr.12005 · Cited by 97
“In the same report, electron microscopy studies of a PGT128-soluble Env SOSIP construct demonstrate that three Fab molecules were bound to the three gp120 outer domains on the face opposite to the CD4bs and oriented at an approximately 120° angle relative to the viral membrane (134).”
BackgroundMethodInfluentialSelf-citationShivatare, S. S., Chang, S., Tsai, T.-I., Ren, C., Chuang, H.-Y., Hsu, L. J., Lin, C.-W., Li, S., Wu, C., & Wong, C. (2013) · Journal of the American Chemical Society · doi:10.1021/ja409097c · Cited by 104
Self-citationProgress in HIV-1 vaccine development
Haynes, B. F., Moody, M. A., Alam, M. S., Bonsignori, M., Verkoczy, L. K., Ferrari, G., Gao, F., Tomaras, G. D., Liao, H., & Kelsoe, G. H. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.04.025 · Cited by 104
Lessons learned from HIV-1 vaccine trials: new priorities and directions
McMichael, A. J., & Haynes, B. F. (2012) · Nature Immunology · doi:10.1038/ni.2264 · Cited by 103
Influences on Trimerization and Aggregation of Soluble, Cleaved HIV-1 SOSIP Envelope Glycoprotein
Klasse, P. J., Depetris, R. S., Pejchal, R., Julien, J., Khayat, R., Lee, J. H., Marozsan, A. J., Cupo, A., Cocco, N., Korzun, J., et al. (2013) · Journal of Virology · doi:10.1128/jvi.01226-13 · Cited by 93
“Negative-stained grids were prepared as previously described (28).”
BackgroundMethodSelf-citationComprehensive Antigenic Map of a Cleaved Soluble HIV-1 Envelope Trimer
Derking, R., Ozorowski, G., Sliepen, K., Yasmeen, A., Cupo, A., Torres, J. L., Julien, J., Lee, J. H., van Montfort, T., de Taeye, S. W., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004767 · Cited by 93
“Thus, different bNAbs have distinct binding motifs on different sides of this glycan, and their angle of approach can also vary [20,25].”
BackgroundSelf-citationBertók, T., Kluková, Ľ., Šedivá, A., Kasák, P., Semak, V., Mičušík, M., Omastová, M., Chovanova, L., Vlček, M., Imrich, R., et al. (2013) · Analytical Chemistry · doi:10.1021/ac401281t · Cited by 96
Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design
Crispin, M., & Doores, K. J. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.02.002 · Cited by 94
Self-citationRichard, J., Prévost, J., Baxter, A. E., von Bredow, B., Ding, S., Medjahed, H., Delgado, G., Brassard, N., Stürzel, C. M., Kirchhoff, F., et al. (2018) · mBio · doi:10.1128/mbio.00358-18 · Cited by 91
“PGT126 binds a conserved region at the V3 loop stem near the N332 glycosylation site (26–28), while 3BNC117 recognizes the CD4-binding site (29).”
McCoy, L. E., Falkowska, E., Doores, K. J., Le, K. M., Sok, D., van Gils, M. J., Euler, Z., Burger, J. A., Seaman, M. S., Sanders, R. W., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005110 · Cited by 90
“However, structural studies have shown that PGT128 contacts the N332 glycan on an engineered gp120 outer domain by interacting with the terminal mannose residues of the D1 and D3 arms [32].”
BackgroundSelf-citationMultivalent glycoconjugates as vaccines and potential drug candidates
Bhatia, S., Dimde, M., & Haag, R. (2014) · MedChemComm · doi:10.1039/c4md00143e · Cited by 100
Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope
Pritchard, L. K., Harvey, D. J., Bonomelli, C., Crispin, M., & Doores, K. J. (2015) · Journal of Virology · doi:10.1128/jvi.01190-15 · Cited by 88
Self-citationLee, J. H., de Val, N., Lyumkis, D., & Ward, A. C. (2015) · Structure · doi:10.1016/j.str.2015.07.020 · Cited by 92
“, 2014), and the Fab variable region of the PGT128 Fab (PDB ID: 3TYG) (Pejchal et al., 2011) were used as the starting model for atomic model building and refinement into the cryoEM map, as the X-ray structures contained protein regions that was of the same construct as the used in the cryoEM complex, and each piece s…”
BackgroundMethodInfluentialSelf-citationThe neoglycolipid (NGL)-based oligosaccharide microarray system poised to decipher the meta-glycome
Palma, A. S., Feizi, T., Childs, R. A., Chai, W., & Liu, Y. (2014) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.01.007 · Cited by 88
“Current Opinion in Chemical Biology 2014, 18:87–94 neutralizing anti-HIV antibodies (bNAbs), cloned from HIV-infected patients that target gp120 N-glycans in addition to the peptide backbone [35,36 ,37].”
BackgroundSelf-citationFab-dimerized glycan-reactive antibodies are a structural category of natural antibodies
Williams, W. B., Meyerhoff, R. R., Edwards, R. J., Li, H., Manne, K., Nicely, N. I., Henderson, R. C., Zhou, Y., Janowska, K., Mansouri, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.042 · Cited by 93
“HIV-1 Env-reactive bnAbs have been described that used long complementary-determining region (CDR) loops to gain access to bnAb epitopes in the Env protein, while also making stabilizing contacts with surrounding glycans (Walker et al., 2009; Bonsignori et al., 2011, 2017; Pejchal et al., 2011; Garces et al., 2014, 20…”
BackgroundCell-to-cell spread of HIV-1 and evasion of neutralizing antibodies
Schiffner, T., Sattentau, Q. J., & Duncan, C. J. A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.10.020 · Cited by 104
Analysis of the SARS-CoV-2 spike protein glycan shield: implications for immune recognitionPreprint
Grant, O. C., Montgomery, D., Ito, K., & Woods, R. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.07.030445 · Cited by 90
Pace, C. S., Song, R., Ochsenbauer, C., Andrews, C. D., Franco, D., Yu, J., Oren, D. A., Seaman, M. S., & Ho, D. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304985110 · Cited by 86
“PGT121 and PGT145 data were generated against a different panel of 162 viruses and have been published previously (7).”
MethodDoores, K. J., Kong, L., Krumm, S. A., Le, K. M., Sok, D., Laserson, U., Garcés, F., Poignard, P., Wilson, I. A., & Burton, D. R. (2014) · Journal of Virology · doi:10.1128/jvi.02905-14 · Cited by 89
Self-citationTong, T., Crooks, E. T., Osawa, K., & Binley, J. Μ. (2012) · Journal of Virology · doi:10.1128/jvi.06938-11 · Cited by 86
“Env-bearing VLPs (Env-VLPs) included WT VLPs (red boxes), E168K N189A mutant WT VLPs (black triangles) that “knock April 2012 Volume 86 Number 7 jvi.asm.org 3575 in” the neutralizing PG9, PG16, and PGT141 MAb epitopes (21), and WT UNC VLPs that bear only uncleaved gp160 (orange diamonds) (19).”
BackgroundInfluentialMimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide
Alam, S. M., Aussedat, B., Vohra, Y., Meyerhoff, R. R., Cale, E. M., Walkowicz, W. E., Radakovich, N. A., Anasti, K. M., Armand, L. C., Parks, R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai7521 · Cited by 85
“S7A), indicating that the bivalent avidity effect could enhance the overall affinity by nearly an order of magnitude and likely mimicking the proposed cross-linking of viral Env spikes during PGT128 neutralization (18).”
BackgroundMethodInfluentialModulation of Glycan Recognition by Clustered Saccharide Patches
(2014) · International Review of Cell and Molecular Biology · doi:10.1016/b978-0-12-800097-7.00003-8 · Cited by 84
Go, E. P., Ding, H., Zhang, S., Ringe, R. P., Nicely, N. I., Hua, D., Steinbock, R. T., Golabek, M., Alin, J., Alam, S. M., et al. (2017) · Journal of Virology · doi:10.1128/jvi.02428-16 · Cited by 86
“All of these bNAbs except 2G12 also contact the gp120 protein surface, typically using long CDRH3 and CDRH1 loops to reach past the “glycan shield” (35, 37).”
BackgroundSelf-citationMorphology and ultrastructure of retrovirus particles
Zhang, W., 1 Institute for Molecular Virology, U. O. M., Cao, S., L. Martin, J., D. Mueller, J., & M. Mansky, L. (2015) · AIMS Biophysics · doi:10.3934/biophy.2015.3.343 · Cited by 74
Zhou, T., Zheng, A., Baxa, U., Chuang, G., Georgiev, I. S., Kong, R., O'Dell, S. J., Shahzad‐ul‐Hussan, S., Shen, C., Tsybovsky, Y., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.02.013 · Cited by 87
“Overall, the recognition and neutralization by VRC-PG05 requiring two glycans and a small protein surface of HIV-1 Env was reminiscent of other HIV-1-neutralizing antibodies with glycopeptide epitopes that pierce the HIV-1 glycan shield (Blattner et al., 2014; Julien et al., 2013; Kong et al., 2013, 2016; McLellan et…”
InfluentialSelf-citationBehrens, A., Harvey, D. J., Milne, E., Cupo, A., Kumar, A., Zitzmann, N., Struwe, W. B., Moore, J. P., & Crispin, M. (2016) · Journal of Virology · doi:10.1128/jvi.01894-16 · Cited by 83
Self-citationRudkin, F. M., Raziunaite, I., Workman, H., Essono, S., Belmonte, R., MacCallum, D. M., Johnson, E. M., Silva, L. M., Palma, A. S., Feizi, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07738-1 · Cited by 80
Self-citationClonal redemption and clonal anergy as mechanisms to balance B cell tolerance and immunity
Burnett, D. L., Reed, J. H., Christ, D., & Goodnow, C. C. (2019) · Immunological Reviews · doi:10.1111/imr.12808 · Cited by 81
Panico, M., Bouché, L., Binet, D., O’Connor, M.-J., Rahman, D., Pang, P., Canis, K., North, S. J., Desrosiers, R. C., Chertova, E. N., et al. (2016) · Scientific Reports · doi:10.1038/srep32956 · Cited by 85
“(a) A two-dye SYPRO-stained (total protein magenta, glycoproteins green) SDS-PAGE gel analysis of early (1) vs.”
MethodLi, H., Zony, C., Chen, P., & Chen, B. K. (2017) · Journal of Virology · doi:10.1128/jvi.02425-16 · Cited by 79
Structural and genetic diversity in antibody repertoires from diverse species
Rios, M. D. L., Criscitiello, M. F., & Smider, V. V. (2015) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2015.06.002 · Cited by 85
“Current Opinion in Structural Biology 2015, 33:27–41 protein gp120, these antibodies are typically not neutralizing, and rarely broadly neutralizing [16,17].”
BackgroundBriney, B. S., Willis, J. R., & Crowe, J. E. (2012) · Genes & Immunity · doi:10.1038/gene.2012.28 · Cited by 75
Haim, H., Salas, I., & Sodroski, J. (2012) · Journal of Virology · doi:10.1128/jvi.02765-12 · Cited by 86
Doria‐Rose, N. A., Louder, M. K., Yang, Z., O'Dell, S. J., Nason, M., Schmidt, S. D., McKee, K., Seaman, M. S., Bailer, R. T., & Mascola, J. R. (2012) · Journal of Virology · doi:10.1128/jvi.06745-11 · Cited by 86
“The Env targets defined by these MAbs include the CD4 binding site (CD4bs) of gp120 (4, 10, 27, 38, 39), a conserved peptidoglycan region of variable loops 1 and 2 (V1V2) (21, 35, 36), the membrane proximal region of gp41 (23, 32), and most recently, a peptidoglycan epitope in the V3 region of gp120 (24, 35).”
BackgroundStructural Characterization of Cleaved, Soluble HIV-1 Envelope Glycoprotein Trimers
Khayat, R., Lee, J. H., Julien, J., Cupo, A., Klasse, P. J., Sanders, R. W., Moore, J. P., Wilson, I. A., & Ward, A. B. (2013) · Journal of Virology · doi:10.1128/jvi.01222-13 · Cited by 76
“664 retains a similar shape and reactivity with VRC PG04 and other broadly neutralizing antibodies (23, 25, 27), as well as sCD4.”
BackgroundMethodSelf-citationApplying Pose Clustering and MD Simulations To Eliminate False Positives in Molecular Docking
Makeneni, S., Thieker, D. F., & Woods, R. J. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00588 · Cited by 79
Computational tools for epitope vaccine design and evaluation
He, L., & Zhu, J. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.03.013 · Cited by 81
“As shown by recent studies, N -linked glycans are major structural elements of several HIV-1 epitopes recognized by bnAbs [8,12,14–16].”
ResultKong, L., de la Peña, A. T., Deller, M. C., Garcés, F., Sliepen, K., Hua, Y., Stanfield, R. L., Sanders, R. W., & Wilson, I. A. (2015) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s1399004715013917 · Cited by 81
“In the crystal structure, PGT128 engages the SOSIP trimer in a similar fashion to the previously described interaction with the gp120 outer domain fragment (Pejchal et al., 2011).”
BackgroundMethodResultInfluentialSelf-citationSaunders, K. O., Nicely, N. I., Wiehe, K. J., Bonsignori, M., Meyerhoff, R. R., Parks, R., Walkowicz, W. E., Aussedat, B., Wu, N. R., Cai, F., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.003 · Cited by 80
“, 2014), PGT128 (PDB: 3TYG; Pejchal et al., 2011), and PGT135 (PDB: 4JM2; Kong et al.”
InfluentialSelf-citationDevelopment of prophylactic vaccines against HIV-1
Schiffner, T., Sattentau, Q. J., & Dorrell, L. (2013) · Retrovirology · doi:10.1186/1742-4690-10-72 · Cited by 84
“These bNmAbs bind epitopes in the V1V2 loop (PG9) and V3 loop base (PGT128), and require an unusually long CDR3 loop to access the peptide ‘floor’ of the canyon whilst also contacting the glycan ‘walls’ [102].”
BackgroundInfluentialMcGuire, A. T., Glenn, J. A., Lippy, A., & Stamatatos, L. (2013) · Journal of Virology · doi:10.1128/jvi.03228-13 · Cited by 83
Recent advances on smart glycoconjugate vaccines in infections and cancer
Anderluh, M., Berti, F., Bzducha‐Wróbel, A., Chiodo, F., Colombo, C., Compostella, F., Durlik-Popińska, K., Ferhati, X., Holmdahl, R., Jovanović, D. J., et al. (2021) · FEBS Journal · doi:10.1111/febs.15909 · Cited by 76
mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies
Xie, Z., Lin, Y., Steichen, J. M., Ozorowski, G., Kratochvil, S., Ray, R., Torres, J. L., Liguori, A., Kalyuzhniy, O., Wang, X., et al. (2024) · Science · doi:10.1126/science.adk0582 · Cited by 75
Self-citationElectrochemical lectin based biosensors as a label-free tool in glycomics
Bertók, T., Katrlík, J., Gemeiner, P., & Tkáč, J. (2012) · Microchimica Acta · doi:10.1007/s00604-012-0876-4 · Cited by 77
Glycan arrays as tools for infectious disease research
Geissner, A., Anish, C., & Seeberger, P. H. (2014) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.11.013 · Cited by 83
Bouvin-Pley, M., Morgand, M., Moreau, A., Jestin, P., Simonnet, C., Tran, L., Goujard, C., Meyer, L., Barin, F., & Braibant, M. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003477 · Cited by 81
The HIV-1 transmission bottleneck
Kariuki, S. M., Selhorst, P., Ariën, K. K., & Dorfman, J. R. (2017) · Retrovirology · doi:10.1186/s12977-017-0343-8 · Cited by 93
Stanfield, R. L., & Wilson, I. A. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0012-2013 · Cited by 87
Self-citationProtein engineering strategies for rational immunogen design
Caradonna, T. M., & Schmidt, A. G. (2021) · npj Vaccines · doi:10.1038/s41541-021-00417-1 · Cited by 75
Glycan-Dependent Immunogenicity of Recombinant Soluble Trimeric Hemagglutinin
de Vries, R. P., Smit, C. H., de Bruin, E., Rigter, A., de Vries, E., Cornelissen, L. A. H. M., Eggink, D., Chung, N. P. Y., Moore, J. P., Sanders, R. W., et al. (2012) · Journal of Virology · doi:10.1128/jvi.01084-12 · Cited by 75
Self-citationZhang, S., Zhou, P., Wang, P., Li, Y., Jiang, L., Jia, W., Wang, H., Fan, A., Wang, D., Shi, X., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.041 · Cited by 67
“Certainly, such a hypothesis would have to be verified in the future (Barnes et al., 2018; Mouquet et al., 2012; Pejchal et al., 2011).”
BackgroundSelf-citationHow HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design
Pancera, M., Changela, A., & Kwong, P. D. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000360 · Cited by 70
Murin, C. D., Julien, J., Sok, D., Stanfield, R. L., Khayat, R., Cupo, A., Moore, J. P., Burton, D. R., Wilson, I. A., & Ward, A. B. (2014) · Journal of Virology · doi:10.1128/jvi.01229-14 · Cited by 74
Self-citationde la Peña, A. T., Rantalainen, K. I., Cottrell, C. A., Allen, J. D., van Gils, M. J., Torres, J. L., Crispin, M., Sanders, R. W., & Ward, A. B. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007920 · Cited by 67
“We also determined binding of bNAbs that target the outer-domain and the V3 glycan region of the Env trimer [37–40].”
BackgroundSelf-citationHoffenberg, S., Powell, R., Carpov, A., Wagner, D., Wilson, A. J., Pond, S. L. K., Lindsay, R. W. B., Arendt, H. E., DeStefano, J., Phogat, S. K., et al. (2013) · Journal of Virology · doi:10.1128/jvi.02827-12 · Cited by 74
“Neutralization of the BG505 pseudovirus by PGT126, which is closely related to PGT128, is surprising since structural studies of cocrystals formed with PGT128 FAb and an outer domain construct containing a mini-V3 loop (eODmV3) indicate that there is binding to a glycan determinant at position N332 (24) which is absen…”
BackgroundInfluentialSelf-citationSharon, J., Rynkiewicz, M. J., Lu, Z., & Yang, C. (2013) · Immunology · doi:10.1111/imm.12213 · Cited by 73
To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1
Griffith, S. A., & McCoy, L. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708227 · Cited by 74
Mata-Fink, J., Kriegsman, B. A., Yu, H., Zhu, H., Hanson, M. C., Irvine, D. J., & Wittrup, K. D. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.11.010 · Cited by 62
Tharakaraman, K., Subramanian, V., Cain, D., Sasisekharan, V., & Sasisekharan, R. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.04.009 · Cited by 62
Correction: Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs
Hoot, S., McGuire, A. T., Cohen, K. W., Strong, R. K., Hangartner, L., Klein, F., Diskin, R., Scheid, J. F., Sather, D. N., Burton, D. R., et al. (2013) · PLoS Pathogens · doi:10.1371/annotation/ed7c0148-97eb-4416-824d-6e6d1aaeceef · Cited by 62
Self-citationFuchs, S. P., & Desrosiers, R. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.68 · Cited by 61
Antibody gene transfer with adeno‐associated viral vectors as a method for HIV prevention
Brady, J. M., Baltimore, D., & Balazs, A. B. (2017) · Immunological Reviews · doi:10.1111/imr.12478 · Cited by 57
Transplanting Supersites of HIV-1 Vulnerability
Zhou, T., Zhu, J., Yang, Y., Gorman, J., Ofek, G., Srivatsan, S. R., Druz, A., Lees, C. R., Lu, G., Soto, C. S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099881 · Cited by 61
“664 Env trimer [7]; antibody PGT128 from donor IAVI 36 in the context of the gp120 outer domain [54]; and antibody PGT135 from donor IAVI 17 in the context of gp120 core [25].”
BackgroundSelf-citationJournal of AIDS & Clinical Research
Kong, L., & Sattentau, Q. J. (2019) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113 · Cited by 59
Progress in HIV-1 vaccine development
Haynes, B. F., & McElrath, M. J. (2013) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328361d178 · Cited by 70
Synthetic carbohydrate antigens for HIV vaccine design
Wang, L. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.10.001 · Cited by 58
Metadata
- Authors
- Pejchal, R., Doores, K. J., Walker, L. M., Khayat, R., Huang, P.-S., Wang, S.-K., Stanfield, R. L., Julien, J.-P., Ramos, A., Crispin, M., Depetris, R., Katpally, U., Marozsan, A., Cupo, A., Maloveste, S., Liu, Y., McBride, R., Ito, Y., Sanders, R. W., Ogohara, C., Paulson, J. C., Feizi, T., Scanlan, C. N., Wong, C.-H., Moore, J. P., Olson, W. C., Ward, A. B., Poignard, P., Schief, W. R., Burton, D. R., & Wilson, I. A.
- Affiliations
- Scripps Research Institute (US)
- University of Washington (US)
- University of Oxford (GB)
- Cornell University (US)
- Progenics Pharmaceuticals (United States) (US)
- National Institutes of Health (US)
- Imperial College London (GB)
- Japan Science and Technology Agency (JP)
- Corresponding author
- Pejchal, Robert
- Doores, Katie J.
- Walker, Laura M.
- Khayat, Reza
- Huang, Po-Ssu
- Burton, Dennis R.
- Wilson, Ian A.
- ORCID
- Doores, Katie J.
- Walker, Laura M.
- Khayat, Reza
- Huang, Po-Ssu
- Wang, Sheng-Kai
- Stanfield, Robyn L.
- Julien, Jean-Philippe
- Crispin, Max
- Depetris, Rafael
- Cupo, Albert
- Liu, Yan
- McBride, Ryan
- Ito, Yukishige
- Sanders, Rogier W.
- Paulson, James C.
- Feizi, Ten
- Wong, Chi-Huey
- Moore, John P.
- Olson, William C.
- Ward, Andrew B.
- Poignard, Pascal
- Schief, William R.
- Burton, Dennis R.
- Wilson, Ian A.
- Venue
- Science
- Published
- 2011-11-25
- Volume
- 334
- Issue
- 6059
- Pages
- 1097-1103
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3280215
- OpenAlex
- W2128579789
- Cited by
- 694
- References
- 75
- Citations by year
- 2026: 23 · 2025: 12 · 2024: 18 · 2023: 19 · 2022: 25 · 2021: 35 · 2020: 34 · 2019: 37 · 2018: 54 · 2017: 54 · 2016: 62 · 2015: 70 · 2014: 69 · 2013: 105 · 2012: 72
- FWCI
- 31.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- Canadian Institutes of Health Research (HFE-224662)
- Engineering and Physical Sciences Research Council (EP/G037604/1, GR/S79268/02)
- National Cancer Institute (Y1-CO-1020, U01CA128416)
- National Institute of General Medical Sciences (Y1-GM-1104)
- National Institute of Allergy and Infectious Diseases (AI-33292, F32AI074372, AI74372, R37AI033292, R56AI084817, P01AI082362, AI082362, R01AI033292, R01AI084817, AI84817)
- National Center for Research Resources (P41RR001209, RR017573, P41RR017573)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- HIV-1, broadly neutralizing antibodies, gp120, glycan shield, V3 loop, antibody penetration
- MeSH terms
- Antibody Specificity, Epitopes, Binding Sites, Antibody, Carbohydrate Conformation, Cell Line, Disaccharides, Glycosylation, Humans, Hydrogen Bonding, Immunoglobulin Fab Fragments, Mannose, Mannosides, Models, Molecular, Mutation, Oligosaccharides, Polysaccharides, Protein Conformation, HIV Antibodies, HIV-1, HIV Envelope Protein gp120, Protein Structure, Tertiary, Crystallography, X-Ray, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.